TY - JOUR
T1 - Cough in Idiopathic Pulmonary Fibrosis
AU - Mann, Jennifer
AU - Goh, Nicole S.L.
AU - Holland, Anne E.
AU - Khor, Yet Hong
N1 - Publisher Copyright:
Copyright © 2021 Mann, Goh, Holland and Khor.
PY - 2021/10/18
Y1 - 2021/10/18
N2 - Chronic cough is experienced by most patients with idiopathic pulmonary fibrosis (IPF). It is often the first symptom and is associated with reduced quality of life, increased rates of depression and anxiety, more severe physiological impairment, and disease progression. Although not fully understood, recent gains in understanding the pathophysiology of chronic cough in IPF have been made. The pathophysiology is likely multifactorial and includes alterations in mucous production and clearance, architectural distortion, and increased cough reflex sensitivity, suggesting a role for targeted therapies and multidisciplinary treatment. Modifiable comorbidities can also induce cough in patients with IPF. There is a renewed emphasis on measuring cough in IPF, with clinical trials of novel and repurposed therapies for chronic cough emerging in this population. This review provides an update on the clinical characteristics, pathophysiology, and measurement of chronic cough in patients with IPF and summarizes recent developments in non-pharmacological and pharmacological therapies.
AB - Chronic cough is experienced by most patients with idiopathic pulmonary fibrosis (IPF). It is often the first symptom and is associated with reduced quality of life, increased rates of depression and anxiety, more severe physiological impairment, and disease progression. Although not fully understood, recent gains in understanding the pathophysiology of chronic cough in IPF have been made. The pathophysiology is likely multifactorial and includes alterations in mucous production and clearance, architectural distortion, and increased cough reflex sensitivity, suggesting a role for targeted therapies and multidisciplinary treatment. Modifiable comorbidities can also induce cough in patients with IPF. There is a renewed emphasis on measuring cough in IPF, with clinical trials of novel and repurposed therapies for chronic cough emerging in this population. This review provides an update on the clinical characteristics, pathophysiology, and measurement of chronic cough in patients with IPF and summarizes recent developments in non-pharmacological and pharmacological therapies.
KW - cough
KW - idiopathic pulmonary fibrosis
KW - interstitial lung disease
KW - patient reported outcome (PRO) measures
KW - prognosis
KW - quality of life
UR - http://www.scopus.com/inward/record.url?scp=85145993196&partnerID=8YFLogxK
U2 - 10.3389/fresc.2021.751798
DO - 10.3389/fresc.2021.751798
M3 - Review Article
C2 - 36188759
AN - SCOPUS:85145993196
SN - 2673-6861
VL - 2
JO - Frontiers in Rehabilitation Sciences
JF - Frontiers in Rehabilitation Sciences
M1 - 751798
ER -